Login to Your Account



Transgene, Sillajen, Lee’s partner to bring liver cancer immunotherapy forward

By Alfred Romann
Staff Writer

Wednesday, April 2, 2014

HONG KONG – A Hong Kong-based biotechnology company that specializes in in-licensing products for marketing in China will work with a partner in South Korea and one in Europe in a late-stage clinical development program for the oncolytic immunotherapy Pexa-Vec (JX-594/TG6006).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription